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Abstract
While significant progress has been made to advance our knowledge of microvascular lesion 
formation, yet the investigation of how stem-like cells may contribute to the pathogenesis of 
microvascular diseases is still in its infancy. We assessed whether the inhibitor of DNA binding 
and differentiation 3 (ID3) contributes to the acquisition of a molecular stem cell-like signature in 
microvascular endothelial cells. The effects of stable ID3 overexpression and SU5416 treatment 
— a chemical inducer of microvascular lesions, had on the stemness signature was determined by 
flow cytometry, immunoblot, and immunohistochemistry. Continuous ID3 expression produced a 
molecular stemness signature consisting of CD133+ VEGFR3+ CD34+ cells. Cells exposed to 
SU5416 showed positive protein expression of ID3, VEGFR3, CD34 and increased expression of 
pluripotent transcription factors Oct-4 and Sox-2. ID3 overexpressing cells supported the 
formation of a 3-D microvascular lesion co-cultured with smooth muscle cells. In addition, in vivo 
microvascular lesions from SuHx rodent model showed an increased expression of ID3, VEGFR3, 
and Pyk2 similar to SU5416 treated human endothelial cells. Further investigations into how 
normal and stem-like cells utilize ID3 may open up new avenues for a better understanding of the 
molecular mechanisms which are underlying the pathological development of microvascular 
diseases.
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Introduction
Prevention and treatment of vascular complications remain a critical problem in the 
management of many microvascular diseases. It is becoming increasingly recognized that 
the pathogenesis of microvascular complications, as well as of several macrovascular 
diseases, includes disordered proliferation of endothelial cells (ECs). There is a strong 
correlation between susceptibility to micro— and macro—vascular complications, 
especially in patients with atherosclerosis contributing to renal disease, diabetic retinopathy, 
and cardiovascular disease (CVD). Furthermore, proliferative microvascular lesions that 
result from a focal budding of ECs and resemble a renal glomerulus are reported to be an 
aggressive angiogenic phenotype associated with a poor prognosis in glioblastoma 
multiforme, non-small cell lung cancer (NSCLC), and severe idiopathic pulmonary arterial 
hypertension (IPAH) (Rojiani et al., 1996; Tanaka et al., 2003; Tuder et al., 1994a). The 
resemblance of EC proliferation of pulmonary plexiform lesions to cancer is supported by 
the fact that ECs in severe IPAH are monoclonal (Lee et al., 1998). The hyper-proliferative, 
apoptosis-resistant, and monoclonal phenotype observed in ECs that form plexiform lesions 
has been put in the context of a quasi malignant process which conceptually can 
accommodate impairment of stem cell differentiation (Rai et al., 2008). The theory that 
malignant transformation depends on a small population of stem-like cells for proliferation 
has received much attention, however, there have been few studies which support a 
pathogenic role for stem cells in vascular proliferative malformations.
There is some evidence that allude to a potential role of inhibitor of differentiation (Id) 
protein 3 in malignant stemness as well as angiogenesis. For instance, induction of ID3 and 
ID3-regulated cytokines has been reported to lead to the acquisition of glioma stem cell 
(GSC) characteristics and angiogenesis (Jin et al., 2011). Since ID3 has been shown to be 
involved in VEGF-dependent EC proliferation (Sakurai et al., 2004) and based on the 
previous hypothesis that VEGF signaling mechanisms are associated with both plexiform 
and glomeruloid lesions (Tuder et al., 2001); it is biologically plausible that ID3 shares a 
common role in the development of microvascular lesions found in severe forms of PAH as 
well as in cancer. The transcription regulator ID3 was shown to be up-regulated in the 
pulmonary vasculature following prolonged exposure of rats to hypoxia (Lowery et al., 
2010) and may affect BMP signaling and the proliferation of human pulmonary artery 
smooth muscle cells (Yang et al., 2013). A number of recent publications associate 
endothelial progenitor cells and dysfunctional resident mesenchymal stem cells with 
vascular remodeling associated with PAH (Diller et al., 2010; Gambaryan et al., 2011; Chow 
et al., 2013). Although direct evidence for the role of ID3 in microvascular lesion formation 
is lacking, the function of Id proteins to prevent cell commitment raises the question of 
whether ID3 may exacerbate the formation of microvascular lesions via its contribution to 
EC stemness.
Improved cell models are critical for understanding the pathogenesis of these types of 
vascular complications and for testing potential new prevention and treatment modalities for 
microvascular disease. Our laboratory has recently observed a significant decrease in 
apoptosis of human cerebral microvascular ECs that overexpress ID3 when compared to 
wild-type. We postulated that ID3 overexpression contributes to the acquisition of a 
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molecular stem cell-like signature in human microvascular ECs and when cultured under 
specific conditions EC ID3+ stem-like cells develop lesions that morphologically resemble 
microvascular proliferative lesions found in other pathologies including cancers and IPAH. 
Therefore, we developed a stable endothelial cell clone that overexpressed ID3 and 
determined whether ID3 contributed to the acquisition of a molecular stem cell-like 
signature. The formation of microvascular lesions has been extensively studied using the 
SU5416/chronic hypoxia (SuHx) rodent model of severe PAH. A chemical antagonist of 
VEGFR1 and 2, SU5416, has been implicated in the growth of pulmonary endothelial 
lesions by expanding surviving CD34+ stem cell-like cells in vitro. Human CD133+ CD34+ 
cells that also express VEGFR3 were previously reported to constitute a phenotypically and 
functionally distinct population of endothelial stem cells. Therefore, we compared the 
following endothelial types EC wt and EC ID3+ to determine the effect of ID3 overexpression 
or exposure to SU5416— a chemical inducer of microvascular lesions had on the molecular 
stem cell-like signature.
Materials and Methods
Chemicals and reagents
The chemical SU5416, an inhibitor of VEGFR tyrosine kinase activity, was purchased from 
Sigma, St Louis, MO. For immunofluorescent imaging, antibodies labeled with Alexa 
Fluor® dyes 633, 488, and 546 were purchased from Invitrogen Life Technologies, CA. For 
culture of ECs B27® serum-free supplement was also purchased from Invitrogen Life 
Technologies. All other reagents are mentioned in the following sections.
Cell culture
The human cerebral microvascular endothelial cell line HCMEC/D3 was obtained from Dr. 
B. Weksler, Weill Medical College of Cornell University, NY (Weksler et al., 2005); and 
will be referred to as endothelial wild-type cells (EC wt) to make a distinction from our 
endothelial ID3 overexpressing clone (EC ID3+). The HCMEC/D3 cells have been shown to 
retain their EC characteristics with a stable normal karyotype, proliferate in response to 
endothelial growth factors, and form capillary tubes in matrix but no colonies in soft agar 
(Weksler et al., 2005). The cells were maintained in DMEM-F12 media with B27® serum-
free supplement. Human pulmonary artery smooth muscle cells (HPASMC) were obtained 
from Invitrogen Life Technologies and were maintained in DMEM-F12 with Smooth 
Muscle Growth Supplement (SMGS). Cells were cultured at 37°C in a humidified 
atmosphere with 5% CO2.
ID3 overexpressing endothelial cells
The HCMEC/D3 cells were transduced with either Precision LentiORF for ID3 (Thermo 
Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP by the trans-
lentiviral packaging kit with Express-in transfection reagent according to the manufacturer’s 
instructions. We used the MOI (multiplicity of infection) of 25 and selected cells that 
overexpressed ID3 with blasticidin S (5μg/ml) as per manufacturer’s instructions. Cells 
expressing TurboGFP were identified by fluorescence microscopy. Using this method, we 
Das et al. Page 3
Microvasc Res. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
cultured for 6 passages to generate a stable endothelial clone that overexpressed ID3 and 
named it EC ID3+.
Fluorescence activated cell sorting (FACS)
After the staining, the cells were washed twice with stain buffer (BD Pharmingen) and 
analyzed using a Guava easyCyte flow cytometer (Millipore). For staining, 1 × 106 cells of 
either EC wt or EC ID3+, were pelleted and incubated for 45 min at 4°C with the following 
antibodies: CD34-PE (BD Pharmingen, 581), CD133 FITC (eBioscience, 13A4) and biotin-
FITC (Miltenyi Biotec), biotin conjugated VEGFR3 (eBioscience, AFL4). For cell cycle 
analysis, cells were harvested, rinsed with PBS, and fixed in suspension in 73% ethanol for 
20 h at −20°C. After incubation at −20°C, the cells were washed with PBS containing 1% 
BSA, stained with PI (10 μg/ml) in PBS containing RNase A (250 μg/ml), and incubated at 
37°C for 30 min in the dark before FACS analysis. Cell cycle distribution was analyzed with 
the Guava easyCyte™ using the CytoSoft software program according to the manufacturer’s 
instructions. The percent DNA content was determined by FACS analysis using PI staining.
Immunohistochemistry
For immunostaining cells were blocked with 3% normal goat serum at 4°C for 1h and then 
incubated with antibodies: anti-ID3 (Santa Cruz Biotechnology 2B11, SC-56712), anti-
VEGFR3 (Santa Cruz Biotechnology M-20, SC-637), or anti-Pyk2 (Santa Cruz 
Biotechnology C-19, SC-1515) overnight at 4°C. After washing with 1X PBS, cells were 
incubated with anti-mouse-IgG Alexa Fluor® 633 for ID3, anti-goat -IgG Alexa Fluor® 488 
for Pyk2, and anti-rabbit -IgG – Alexa Fluor® 546 for VEGFR3, for 2 h. Cells were washed 
with PBS and then placed on cover slips with Fluoromount-G™ slide mounting medium 
(Electron Microscopy Science, Hatfield, PA). For immunofluorescence studies of Oct-4 and 
Sox-2, cells were treated with SU5416. Next, magnetic-activated cell sorted (MACS) 
CD31+ cells were treated with SU5416 [5μM] treatment and grown in chamber slides for 
four days. For immunostaining cells were blocked with 3% normal goat serum at 4°C for 1h 
and then incubated with antibodies: anti-CD31 (Santa Cruz Biotechnology, PECAM-1, H-3, 
SC-37664), anti Oct-4 (Cell Signaling Technology, 2750S), or anti Sox-2 (Santa Cruz 
Biotechnology Y-17, SC-17320) overnight at 4°C. After washing with 1X PBS, cells were 
incubated with anti-mouse-IgG Alexa Fluor® 633 for CD31, anti-goat -IgG Alexa Fluor® 
488 for Sox-2 and anti-rabbit-IgG Alexa Fluor® 546 for Oct-4 for 2h. Cells were washed 
with PBS mounted with Fluoromount-G™ reagent. For immunofluoresence of spheroids, 
approximately 100 spheres were fixed with 4% paraformaldehyde in 1% Triton X-100, 
washed in PBS, serially dehydrated in methanol (25%, 50%, 75%, 95% & 100%). Then 
spheroids were rehydrated in descending percentage of methanol and washed in PBS. 
Spheroids were incubated in 3% normal goat serum (Vector Lab, Burlingame, CA) at 4°C 
for 24h and washed in PBS with 0.5% Tween 20 (PBST). Next, spheroids were incubated 
with primary antibodies anti-Sox-2 (Santa Cruz Biotechnology Y-17, SC-17320), and anti-
Oct-4 (Cell Signaling Technology, 2750S) for 48h at 4°C, washed in PBST and incubated 
with anti-rabbit-IgG Alexa Fluor® 546 for Oct-4 and anti-goat-IgG Alexa Fluor® 488 for 
Sox-2. Spheres were mounted in chamber slides and fluorescence staining analyzed. All 
samples were analyzed using a Nikon C1 laser scanning confocal microscope.
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Immunofluorescence of ID3, CD34, αSMA, CD31, Oct4, or Sox2 positive cells was semi-
quantitatively evaluated by assigning a score for the intensity of the immunofluorescence 
(IF) and for the proportion of cells immunostained. The product of these two values was 
taken to give the overall IF (total score). The intensity of the immunofluorescence (intensity 
score) was stratified into four categories: 0, no IF; 1, weak IF; 2, moderate IF; and 3, strong 
IF. Higher than 1 IF was considered positive for ID3, CD34, αSMA, CD31, Oct4, or Sox2 
in cells. We counted 100 immunofluorescent cells in each group. In control, cells that were 
scored 1 IF were counted and expressed as a percentage. In SU5416 group, cells that were 
scored 2 IF and 3 IF were counted and expressed as a percentage.
Cell differentiation
The EC ID3+ clone was grown for 7d in DMEM-F12 media with B27® serum-free 
supplement in ultra-low attachment plates followed by 3 days in culture media (DMEMF12 
plus 5% FBS). This procedure was repeated 6 times for a total of 60 days under these 
conditions. Afterwards, EC ID3+ stem-like cells were maintained in culture media for 28 
days in the control group. For differentiation, EC ID3+ stem-like cells were cultured in either 
SMGS plus DMEM-F12 or neurobasal media plus nerve growth factor-7S (Sigma), 
Glutamax, and N2 supplement for a total of 28 days. Cells were grown in LabTek(R) II 8 
chambered #1.5 German coverglass system, NUNC (Thermo Fisher Scientific Inc.). We 
determined cell differentiation at days 7, 14, and 28 with antibodies-CD34 (control); α-
smooth muscle actin (smooth muscle marker); and β-tubulin III (neuron marker). Nuclei 
were counterstained with DRAQ5® (Cell Signaling).
Western blotting
Whole cell lysates were prepared with lysis buffer containing [25 mM Tris-HCl buffer (pH 
8.0), 150mM NaCl, 0.2% NP-40, 10% glycerol, 8 mM β-glycerophosphate, 2.5 mM sodium 
pyrophosphate, 10 mM NaF, 0.2 mM Na3VO4, 1 mM DTT and 10 μl/ml protease inhibitor 
cocktail (Sigma Aldrich). Proteins were quantified using the Bradford Assay Reagent (Bio-
Rad) according to the manufacturer’s instructions. Proteins (35–75 μg) were separated by 
10% SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). 
Membranes were blocked with 5% nonfat milk and incubated with the following antibodies: 
ID3 (Cal BioReagent), CD34 (Santa Cruz Biotechnology), and VEGFR3 (Santa Cruz 
Biotechnology). Membranes were then incubated with horseradish peroxidase-conjugated 
secondary IgG antibodies and visualized with ECL Plus Western blot reagents (GE 
Healthcare, Amersham). The membranes were re-probed for β-actin as loading control. 
Electrochemiluminescence (ECL) intensity of detected target proteins was imaged and 
quantified with a Bio-Rad Versa Doc instrument. All immunoblots were completed a 
minimum of three times for each experiment.
Endothelial spheroid and 3-D cell culture
Cells used for sphere assay were first magnetic-activated cell sorted (MACS) CD31+ 
endothelial cells. In brief, ECs were isolated using the Dynal MPC®-L Magnetic Particle 
Concentrator (Invitrogen Dynal AS, Oslo, Norway) and anti-CD31 conjugated magnetic 
Dynabeads® (Invitrogen Dynal AS) according to the manufacture’s protocols. Concentrated 
CD31-positive ECs were suspended in serum-free stem cell medium containing DMEM/F12 
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(1:1) supplemented with B27®. For EC spheroid generation, approximately 100–150 cells 
per well were seeded in an ultra low-attachment 96-well plate (Corning Inc, Lowell, MA) 
with or without SU5416 treatment for four days. SU5416 was added on the day of cell 
seeding. For 3-D cell culture, equal proportions of EC and HPASMC were seeded in 
DMEM/F12 (1:1) containing B27® serum-free supplement. Next, EC spheroids were 
transferred into a cell culture insert precast with collagen matrix and reduced growth factor 
Matrigel for a 24-well plate (Corning Inc, Corning, NY). The DMEM/F12 serum-free B27® 
medium was carefully added into the cell culture insert, placed into the 24 well plate and 
incubated at 37°C for 90 days. Culture medium was replenished every 15 days.
Preparation of histological tissues
The 3-D microvascular lesions were harvested after 90 days followed by routine paraffin 
embedding, histological processing and staining. In brief, paraffin embedded spheroid 
sections were placed in xylene for 10 min and then the slides were gradually re-hydrated in 
successive steps with ethanol (100%, 95%, 70%) and PBS, pH 7.4. Next, the slides were 
stained with hematoxylin solution (Mayer, Fluka Biochemika), washed with PBS, and 
dehydrated in methanol (25%, 50%, 75%, 95%). After 95% methanol, we stained the slides 
in eosin (Fisher Scientific) and immersed the slides in 95% methanol to remove excess stain 
followed by 100% methanol for 10 min. The stained sections were then mounted with a 
cover glass using Permount (Fisher Scientific).
Immunohistochemistry of 3-D microvascular lesions
Slides of tissues generated by the 3-D cell culture were histologically prepared for 
microscopy as described previously. For immunofluorescence imaging studies, slides were 
incubated with primary antibodies anti-CD34 (Santa Cruz Biotechnology C-18, SC-7045), 
α-SMA(Santa Cruz Biotechnology B-4, SC-53142), and anti-ID3 (Santa Cruz 
Biotechnology C-20, SC-490) for 12h at 4°C, washed in PBST, and incubated with anti-
mouse-IgG Alexa Fluor® 633 for α-SMA, anti-goat-IgG Alexa Fluor® 488 for CD34, and 
anti-rabbit-IgG Alexa Fluor® 546 for ID3 for 12h. After washing, cells were mounted and 
samples were analyzed using a Nikon C1 laser scanning confocal microscope.
Immunohistochemistry of in vivo pulmonary vascular lesions
In vivo pulmonary arterial lesions were generated by the combination of SU5416 treatment 
and chronic hypoxia as described previously (Taraseviciene-Stewart et al., 2001). Lung 
vasculature tissues were obtained from our collaborator, Dr. Norbert F. Voelkel, MD, 
Professor of Pulmonary Research and Director of the Victoria Johnson Center for 
Obstructive Lung Diseases. The experimental protocol was approved by the Animal Care 
and Use Committee of the Virginia Commonwealth University, Richmond, VA. In brief, 
rats were given a single dose of 20 mg/kg of SU5416 on day 1 and were then exposed to 3 
weeks of hypoxia as described previously (Taraseviciene-Stewart et al., 2001). Controls 
included vehicle alone and exposure to hypoxia. The methods for immunohistochemistry 
(triple labeling) of lung vascular lesions with ID3, VEGFR3, and Pyk2 are similar to what 
was described in the immunofluorescence cell staining section. All tissue samples were 
analyzed using a Nikon C1 laser scanning confocal microscope.
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Statistical analyses
All statistics were performed using VassarStats statistical software (Richard Lowry, 
Poughkeepsie, NY, USA). One-way analysis of variance (ANOVA) was performed to detect 
any differences between groups. If the result of the ANOVA is significant, pair wise 
comparisons between the groups were made by a post-hoc test (Tukey’s HSD procedure).
Results
ID3 induces a molecular stem cell-like signature in microvascular cells
Endothelial stem/progenitor cells have been reported in circulating peripheral blood while 
there is also evidence for endothelial stem cells that reside locally in the endothelium of the 
vessel wall. Given the biological significance of Id proteins for the maintenance of stemness, 
we asked whether overexpression of ID3 could induce a molecular stem-cell like signature 
in adult microvascular ECs. To address this question, adult human microvascular ECs were 
transduced using a MOI of 25 with either the Precision LentiORF for ID3 overexpression or 
control empty lentiviral vector pLEX-JRED/TurboGFP according to the manufacturer’s 
instructions. Cells were then seeded at clonal density and selected with blasticidin S (5μg/
ml).
Vascular remodeling in the lungs of patients with IPAH was reportedly associated with 
elevated levels of circulating CD133+ CD34+ stem cell-like endothelial progenitor cells. To 
determine whether EC ID3+ acquire a molecular stem cell like signature, we performed flow 
cytometry. We first determined the effect of ID3 on the cell surface expression of stem cell 
marker CD133 in cells that were positive for endothelial marker CD34 by two color flow 
cytometry. Figure 1A is a representative flow cytometry data analysis of EC wt and EC ID3+, 
respectively. In the ID3 overexpressing cells, we observed that approximately 36% of the 
total cell population was positive for stem-cell markers CD133 and CD34 compared to only 
5% in the wild-type cell population (Fig. 1C). This increase in CD133+ CD34+ cells in the 
EC ID3+ population was statistically significant. Currently, there is no agreement about 
which combination of cell surface markers (i.e. CD133+ VEGFR2+ CD34+) best identify a 
population of endothelial stem cell-like cells. Human CD133+ CD34+ cells that also express 
VEGFR3 were reported to constitute a phenotypically and functionally distinct population of 
endothelial stem cells (Salven et al., 2003). Therefore, we determined VEGFR3 expression 
in EC ID3+ (Fig. 1B). As shown in Fig. 1D, we observed that approximately 36% of the total 
EC ID3+ population was positive for endothelial stem markers VEGFR3 and CD34 
compared to only 7% in wild-type cells (Fig. 1D). The increase in VEGFR3+ CD34+ cells in 
the EC ID3+ population was statistically significant. Taken together these results show a 
significant CD133+ VEGFR3+ CD34+ — molecular stem cell-like signature in the EC ID3+ 
population.
As stem cells mature, they spend less time in G0/G1 phase due to a more robust proliferative 
ability as they move toward terminal differentiation. Proliferative quiescence is a state 
observed in stem cells which reside longer in the G0/G1 phase of the cell cycle; and it has 
been hypothesized that quiescence may prevent against the depletion of the stem cell 
population. Since ID3 is a known inhibitor of differentiation, we postulated that EC ID3+ 
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may show increased proliferative quiescence. Therefore, we asked the question of whether 
ID3 increased the number of cells distributed in the G0/G1 phase of the cell cycle as a 
biological indicator of proliferative quiescence. In Fig. 2A, FACS data shown are 
representative histograms from three independent experiments showing the effect of ID3 
overexpression compared to wild-type ECs. Our flow cytometery experiments revealed that 
approximately 71% of the DNA content in EC ID3+ resided in the G0/G1 phase compared to 
only 58% of the wild-type cells. Thus, EC ID3+ showed a statistically significant 1.2-fold 
increase in G0/G1 phase cells (Fig. 2B). The percentage of DNA content in S phase 
decreased from approximately 11% in EC wt to 6% in EC ID3+. Thus, ID3 significantly 
reduced the number of cells in S phase by more than 0.5-fold (Fig. 2B). The EC ID3+ also 
showed a similar decrease in % DNA content in G2/M phase from approximately 9% in 
wild-type cells to 5% in the EC ID3+ population (Fig. 2B). Our data suggest that in the 
EC ID3+ population there is a significant increase in the number of cells that reside in the 
G0/G1 phase which is indicative of proliferative quiescence. Since a higher proliferative 
capacity may exhaust a stem cell population, this observed increase in G0/G1 phase by 
EC ID3+ may help to maintain a stem cell-like state by slowing cell cycle progression.
Microvascular cells treated with SU5416 show positive protein expression of ID3 and 
VEGFR3
The formation of microvascular lesions has been extensively studied using the SU5416/
chronic hypoxia (SuHx) rodent model of severe PAH (Taraseviciene-Stewart et al., 2001; 
Oka et al., 2007). A chemical antagonist of VEGFR1 and 2, SU5416, has been implicated in 
the growth of pulmonary endothelial lesions by expanding surviving CD34+ stem cell-like 
cells in vitro. Whether SU5416 treatment can lead to the expression of a molecular stem 
cell-like signature just as we observed in the EC ID3+ has not been reported. Furthermore, it 
has not been determined whether VEGFR1/2 blockade by SU5416 treatment may actually 
increase the expression of other VEGF receptor family members (Nicolls et al., 2012). We 
have previously shown increased VEGFR3 expression in CD34+ cells from EC ID3+ 
population (Fig. 1B). Since SU5416 treatment is suspected of expanding a CD34+ stem cell-
like population which could participate in the formation of the pulmonary microvascular 
lesions found in the SuHx rodent model of severe PAH, we determined whether SU5416 
treatment would increase VEGFR3 expression in EC wt. The wild-type ECs were treated 
with SU5416 [3μM] for 3h. As shown in the representative immunofluorescent images (Fig. 
3A), SU5416 treatment increased both VEGFR3 and ID3 expression when compared to the 
vehicle control cells. SU5416 treatment showed a statistically significant increase in both 
VEGFR3+ and ID3+ immunostained cells of approximately 65% and 44%, respectively, 
compared to less than 5% in the vehicle control. Next, we confirmed the results from the 
immunofluorescent experiments by measuring the protein levels of ID3, VEGFR3, and 
CD34 induced by SU5416 treatment. Western blots showed that SU5416 treatment 
increased the relative ratio of ID3 greater than 5-fold and VEGFR3 greater than 15-fold 
compared to control (Fig. 3C). Our results also showed an approximate 10-fold increase in 
the protein level of endothelial marker CD34. We find it interesting that SU5416 chronic 
treatment had been previously reported to provide a selection pressure resulting in an 
increase in CD34+ cell population that trans-differentiated into smooth muscle (SM)-like 
and neuronal-like cells. In contrast, our experiments showed that short-term exposure to 
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SU5416 of 3h significantly increased cellular levels of CD34; this cannot be explained by 
selection pressure. The increased expression of ID3, VEGFR3, and CD34 induced by 
SU5416 treatment aligns in a pattern of an angiogenic signaling pathway because all three 
proteins have been reported to be associated with new vessel formation.
Dysfunctional bone morphogenetic protein (BMP) signaling has been implicated in IPAH 
(Spiekerkoetter et al., 2013). We were intrigued by a study that showed BMP treatment 
differentially up-regulated proline rich tyrosine kinase 2 (Pyk2) in pulmonary artery cells 
from patients with severe IPAH compared to normal subjects (Fantozzi et al., 2005). Pyk2 is 
particularly abundant in lung and brain tissues; and Pyk2 kinase activity is reported to 
control pulmonary vascular EC spreading, migration, morphogenesis, as well as pulmonary 
vein and artery angiogenesis ex vivo. Therefore, the next set of experiments addressed the 
question of whether Pyk2 expression was also affected by exposure to SU5416. As shown in 
Fig. 3A, SU5416 treated EC wt showed an increased number of cells that immunostained 
Pyk2+ to approximately 70% (Fig. 3B). This increase in Pyk2 expression by SU5416 in the 
human ECs may help to bridge a mechanistic signaling link between the previously reported 
abnormal Pyk2 up-regulation observed in the cultured ECs of IPAH patients and the well-
established SuHx animal model of PAH.
Microvascular cells treated with SU5416 express pluripotent transcription factors Oct-4 
and Sox-2
Exposure to SU5416 has been shown to select for cells that express the stem cell marker 
CD34 that were differentiated into SM-like and neuronal-like cells (Sakao et al., 2007). Our 
present experiments showed increased ID3 expression from SU5416 treatment (Fig. 3C) and 
we suspect that SU5416 may contribute to stemness by modulating pluripotent transcription 
regulators such as ID3. The continuous expression of Oct-4 and Sox-2 in fetal ECs has been 
reported to induce pluripotency. More recently we have identified increased Oct-4+ cells 
within pulmonary microvascular lesions and the surroundings of remodeled vessels at 7 
weeks in the SU5416 treated rodent model of PAH. Consequently, next we determined 
whether exposure to SU5416 could elicit the expression of Oct-4 and Sox-2 in human 
microvascular ECs as we previously observed with ID3. EC wt was treated with SU5416 
[5μM] for 3h and then cultured in fresh media for four days. In Fig. 4A, representative 
images of immunofluorescent stained Oct-4+ and Sox-2+ EC wt showed that SU5416 
treatment dramatically increased the expression of these transcription factors. 
Approximately 90% of the EC wt treated with SU5416 were Oct-4+ and Sox-2+ compared to 
vehicle control which was statistically significant (Fig. 4B). In addition, the cells stained 
90% positive for CD31 which is a known marker found in EC stem cell-like cells (Fig. 4B). 
Interestingly, our data showed that SU5416 exposure resulted in a robust expression of 
pluripotency characterizing factors at day 4 even while the cells had only been exposed to 
the VEGFR blocker for 3h. One possible explanation for the long-lasting induction of these 
molecules by a 3h chemical exposure is that ECs concentrate SU5416. For example, a 2h 
exposure to 4 μM of SU5416 has been shown to produce an intracellular concentration of 
450 μM in the HUVEC cell line (Mendel et al., 2000). Thus, the sustained induction of 
Oct-4+ and Sox-2+ expression following an acute exposure is likely the result of the SU5416 
being retained in ECs even when it has been removed from the culture medium.
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Sphere-forming assays are widely used in stem cell biology to culture cells under non-
adherent conditions in order to characterize stemness. Colony forming units of ECs are 
typically enriched in CD34+ CD133+ cells. Intriguingly, colony forming ECs from 
individuals with IPAH have been shown to produce large cell clusters and angioproliferative 
lesions in the Matrigel Plug xenograft model. As an alternative to our experiments in 
monolayer cultures (Fig. 4), we cultured ECs using a sphere forming assay in order to verify 
whether SU5416 induced Oct-4 and Sox-2 in a more homogeneous population of stem cell-
like cells. The sphere forming assay has been widely used to select for stem cell-like cells 
under serum-free culture conditions. Since each sphere is derived from a single cell and 
therefore clonal, the more stringent cell selection conditions that arise from SU5416 
treatment in conjunction with the sphere forming assay allowed us to examine an association 
of clonal cell growth with the stemness profile so far identified. Prior to the sphere assay, 
wild-type endothelial cells were enriched by magnetic-activated cell sorting for CD31+ cells. 
Next, EC wt were seeded at clonal density and cultured as spheroids in DMEM-F12 B27® 
serum-free media with or without SU5416 treatment as described previously in the Materials 
and Methods Section. Diameter was measured using a total of 15 endothelial spheroids with 
a minimum diameter of 70μm were counted in each experimental group. Data were analyzed 
by ANOVA; Tukey HSD test for multiple comparisons. In Fig. 5A, immunofluorescence 
staining of Oct-4 and Sox-2 was significantly greater in SU5416 treated cells and confirmed 
our previous data of EC wt cultured as a monolayer (Fig. 4A). The EC spheroid consisted of 
an acellular core in the vehicle control experiments (Fig. 5A, top row) as expected when the 
EC wt are cultured under serum-free conditions. In clear contrast, the EC wt spheroids treated 
with SU5416 showed a significant growth (diameter) increase at days 2 and 4 when 
compared to vehicle controls (Fig 5B). Unlike the previous studies where SU5416 treatment 
of EC wt grown as a monolayer selected for a CD34+ endothelial stem cell-like population, 
the sphere forming assay under serum-free conditions selects for a VEGFR blockade-
triggered homogeneous population of stem cell-like cells. This is an important novel finding. 
The observed increase in spheroid diameter correlated with a robust expression of Oct-4 and 
Sox-2. Taken together, our findings suggest that SU5416 exposure may not only expand a 
population of CD34+ endothelial stem cell-like cells as a consequence of VEGFR1 and 2 
blockade, but additionally or alternatively activate biological pathways that increase the 
expression of pluripotent signaling molecules. Chemical-induced reprogramming has been 
shown by others to be a novel approach to generate pluripotent stem cells (Li et al., 2011). 
Whereas the continuous expression of ID3 and Oct-4 can reprogram mouse embryonic 
fibroblasts into neural stem cells (Moon et al., 2012), the chemical induction of pluripotent 
transcription factors in adult human microvascular ECs by SU5416 treatment under 
conditions of the sphere assay has not been previously reported. This result leads us to 
postulate that SU5416 exposure may contribute to the growth of stem cell-like cells by 
inducing pluripotent factors: ID3, Oct-4, and Sox-2.
EC ID3+ stem-like cells display a pluripotent morphology
Since our previous data showed that ID3 induced a molecular stem cell-like signature, we 
further determined whether the EC ID3+ clone was morphologically pluripotent. To 
determine pluripotency, we generated EC ID3+ stem-like cells as described in the Materials 
& Methods section. Next, the EC ID3+ stem-like cells were seeded in monolayer and cultured 
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with either neuronal or smooth muscle differentiation medium. At 7 days the EC ID3+ stem-
like cells were assessed by phase-contrast microscopy for morphological changes. As shown 
in Fig. 6A, the untreated EC ID3+ stem-like cells appeared as a monolayer of cuboidal, 
broad, flat cells. After 7 day treatment with smooth muscle differentiation medium, the 
stem-like ECs began to show a heterogeneous phenotype of both cuboidal cells as well as 
the characteristic elongated spindle shape of a VSMC (Fig. 6A). Likewise after neuronal 
induction, EC ID3+ stem-like cells displayed changes in morphology including shrinkage of 
cytoplasm, formation of axon— and dendrite—like cytoplasmic projections (Fig. 6A). Cell 
differentiation markers were determined using immunofluorescence at days 7, 14, and 28. 
For immunofluorescence imaging studies, slides were incubated with primary antibodies 
anti-CD34, α-smooth muscle actin (α-SMA), and β-tubulin III. As shown in Fig. 6B, smooth 
muscle-like cells immunostained positive for the α-SMA; and negative for both neuronal 
marker β-tubulin III and endothelial stem cell marker CD34. The immunofluorescence 
images indicated that these cells persisted to show an elongated spindle shape beyond 7 
days. Furthermore, we observed the following morphological changes of a shrinking 
cytoplasm and a more rounded nuclei compared to the untreated EC ID3+ stem-like cells. As 
shown in Fig 6B, neuronal-like cells immunostained positive for neuronal marker β-tubulin 
III; and negative for both markers CD34 and α-SMA. Immunofluorescence images of 
neuronal differentiation (Fig. 6B) showed that the cytoplasm of EC ID3+ stem-like cells 
began to retract toward the nucleus, forming contracted cell bodies with extended 
cytoplasmic extensions. Beyond 7 days, the EC ID3+ stem-like cells treated with neuronal 
differentiation media continued to form contracted cell bodies with extended cytoplasmic 
extensions. These extensions morphologically resembled axon— and dendrite—like 
processes up to 28 days. Although these histological changes consistent with smooth muscle 
and neuronal differentiation were seen in EC ID3+ stem-like cells, they do not show that 
these cells are, in fact, functional SMCs or neurons. These results however do confirm that 
the EC ID3+ stem-like cells are morphologically pluripotent under these specific conditions.
EC ID3+ stem-like cells form a 3-D microvascular lesion
Based on the morphological pluripotency of EC ID3+ stem-like cells, we postulate that these 
endothelial stem-like cells may serve as a human model system for studying microvascular 
lesions. Our FACS analysis of EC ID3+ indicated that overexpression of ID3 increased the 
levels of VEGFR3. Interestingly, VEGFR3 is reported to be highly expressed on glioma 
tumor endothelium (Grau et al., 2007); and we recently communicated that VEGFR3 
signaling contributes to angioobliterative pulmonary hypertension (communicated, Ayers et 
al. Pulmonary Circulation). Taken together, this data is consistent with the hypothesis that 
EC ID3+ stem-like cells have utility in the study of microvascular lesions involved in other 
pathologies such as pulmonary plexiform lesions. For instance, morphologically and 
immunohistochemically, the plexiform lesion present in severe pulmonary hypertension was 
reported to resemble the neovascularization associated with the brain tumor glioblastoma 
multiform (Tuder et al., 1994a). To determine whether EC ID3+ stem-like cells may serve as 
a human model of microvascular lesions, we cultured EC ID3+ stem-like cells with 
pulmonary arterial SMCs to mimic an in vitro 3-D pulmonary microvascular lesion.
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Cell culture assays that stimulate the differentiation of ECs into capillary-like tubes are 
usually performed on 3-D matrices consisting of fibrin, collagen or Matrigel that mimic the 
in vivo environment. Based on our previous findings that showed ID3 overexpression 
significantly increased a molecular stem cell-like signature of CD133+ VEGFR3+ CD34+, 
we evaluated the differentiation capacity of these cells when cultured with pulmonary 
arterial SMCs using a modified 3-D culture protocol (Kalabis et al., 2012). Figure 7A shows 
a diagrammatic representation of the protocol used to prepare the 3-D microvascular lesions. 
Briefly, equal proportions of cells from either EC wt or EC ID3+ were seeded with SMCs in 
serum-free B27® supplemented DMEM-F12. After formation of EC/SMC spheroids, the 
spheroids were transferred into pre-cast collagen matrix and Matrigel containing transwell 
inserts. Next, serum-free DMEM-F12 supplemented with B27® was used to fill transwell 
carriers containing the inserts and incubated at 37°C for 90 days with a fresh change of 
medium every 15 days. After allowing the EC/SMC spheroids to self-organize and grow for 
90 days, 3-D cell cultures were harvested and processed using routine paraffin embedding 
and histological staining techniques. Under these conditions spheroids cultured with EC wt 
did not survive for more than 15 days and there was no tube formation (data not shown). 
However, spheroids containing cells from the EC ID3+ developed capillary-like structures. 
Figure 7B shows a representative phase photograph of a tube-like structure (blue arrow) 
connected to a spheroid (red arrow). The number of tube structures in EC ID3+/SMC 
spheroids gradually increased during the 90 day time period as shown in Fig. 7C. Although 
the EC wt/SMC culture did not survive to form spheroids, our data suggest that ID3 may 
give ECs an advantage in surviving serum-free 3-D culture. If EC spheroids are not exposed 
to growth factors such as in our serum-free conditions, it has been demonstrated that the 
center cells undergo apoptosis leaving an EC spheroid consisting of an acellular core (Korff 
et al., 1998). This may explain why the EC wt did not survive as they were not in a 
proliferative quiescent state and relied heavily on growth factors. Upon histological 
examination, the tube-like structures showed a well-defined and robust cord (Fig. 7D). The 
small circular morphology of the ECs are indicated by the green arrow while the bigger 
spindle shaped SMCs are shown by the black arrow. As shown in Fig. 7E, the morphology 
of the 3-D microvascular lesion resembled a glomeruloid body with lumen-like structures. 
This cross-sectional view of the lesion showed a viable and intact cellular core from which 
the tube-like structures originate. The endothelial nature of tube structures as well as the 
contribution of SMCs was confirmed by staining for the endothelial marker CD34 and the 
SMC marker α-SMA. As shown in the immunofluorescence image (Fig. 7F), SMCs 
organized mainly along the tube-like structures while the majority of ECs composed both 
the spherical core as well the tube-like structures. Approximately, 45% of the cells 
immunostained positive for the SMC marker and 90% stained positive for the EC marker 
(Fig. 7G). These findings suggest that the SMCs terminally differentiated or could not 
proliferate in the serum-free conditions based on the initial equal cell seeding ratio of EC/
SMC. Although ID3 overexpression did not prevent the differentiation of ECs into tube-like 
structures, our findings suggest that ID3 overexpression prevented the terminal 
differentiation of a core of ECs that was able to support the growth of a glomeruloid 
microvascular lesion and tube-like structures for the entire 90 day period. Thus, EC ID3+ 
stem-like cells plus their progeny eventually outnumbered the SMCs by the end of the 
experiment. Our results show that under these culture conditions, EC ID3+ stem-like cells 
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can form a 3-D microvascular lesion that morphologically resemble glomeruloid 
microvascular lesions that have been reported in glioblastoma multiform and plexiform 
lesions of IPAH.
In vivo pulmonary vascular lesions overexpress ID3, VEGFR3, Pyk2
Our previous experiments with SU5416 treated EC wt showed a significant increase in the 
expression levels of ID3, VEGFR3, and Pyk2. SU5416 treatment plus chronic hypoxia of 
rodents is a well-known model of severe PAH that produces plexiform lesions that closely 
resemble those found in humans (Taraseviciene-Stewart et al., 2001). To determine whether 
formation of pulmonary vascular lesions caused by SU5416 plus chronic hypoxia treatment 
in rodents affected the level of these markers, we performed immunohistochemistry on lung 
tissue from rodents using antibodies for ID3, VEGFR3, and Pyk2. As shown in Fig. 8A, the 
cells that line the lumen of the pulmonary artery in both the vehicle control and the chronic 
hypoxia groups form a uniform monolayer. In contrast, the cells lining the lumen from the 
SU5416-treated lung exposed to chronic hypoxia for 3 wk were piled on top of each other 
leading to lumen obliteration. In the endothelial lesions from the SuHx treated lungs, we 
observed that approximately 80% of the cells expressed ID3, VEGFR3, and Pyk2 compared 
to only 10% of the cells in the control animals. In the 3 week chronic hypoxia group, we 
observed that approximately 50% of the cells expressed all three markers. As shown in Fig. 
8B, expression of all three markers was significantly higher in the SU5416 + hypoxia 
treatment group compared to hypoxia alone group.
Discussion
Many investigators and laboratories have made important contributions which have greatly 
advanced our knowledge of the cellular and molecular mechanisms which control the 
development of microvascular lesions (Hassoun et al., 2009); yet the investigation of stem 
cells and their roles in vessel remodeling is still in its infancy. Our study showed that ID3 
contributes to the acquisition of a molecular stem cell-like signature in human microvascular 
ECs and when cultured under specific conditions EC ID3+ stem-like cells formed a 3-D 
microvascular lesion that morphologically resembled glomeruloid microvascular lesions 
known to be found in other pathologies including glioblastoma, NSCLC, and IPAH (Rojiani 
et al., 1996; Tanaka et al., 2003; Tuder et al., 1994a). Based on the morphological 
pluripotency of EC ID3+ stem-like cells, we postulate that these endothelial stem-like cells 
may serve as a human model system for studying microvascular lesions. In this study, we 
compared the following endothelial types EC wt and EC ID3+ and determined the effects of 
ID3 overexpression or exposure to SU5416— a chemical inducer of microvascular lesions 
had on the molecular stemness signature. The major findings of our investigations are: (i) 
continuous expression of ID3 produced a molecular EC stemness signature consisting of 
CD133+ VEGFR3+ CD34+ cells; (ii) EC wt exposed to the VEGFR1/2 inhibitor—SU5416 
showed positive protein expression of ID3, VEGFR3, CD34; (iii) EC wt exposed to SU5416 
showed increased expression of pluripotent transcription regulators ID3, Oct-4, and Sox-2; 
(iv) EC ID3+ stem-like cells supported the formation of a 3-D microvascular lesion co-
cultured with SMCs; and (v) in vivo microvascular lesions induced by SU5416 plus chronic 
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hypoxia in rodents showed an increased expression of ID3, VEGFR3, and Pyk2 similar to 
exposed EC wt.
Given the biological significance of Id proteins in stemness, we asked whether 
overexpression of ID3 would produce in ECs a molecular signature of stemness. In our 
studies we showed that either continuous ID3 overexpression or SU5416 treatment altered 
the levels of stemness markers in ECs. Our data show that ID3 lead to the expression of 
CD133+ CD34+ cells that also express VEGFR3, a molecular signature previously reported 
to identify endothelial stem cells (Salven et al., 2003). Our results also illustrate that the 
expression of the pluripotent transcription regulators ID3, Oct-4, and Sox-2 may be novel 
molecular targets of SU5416. This finding is significant in that it points toward a potential 
mechanism of chemical-induced stemness in not only the SuHx model of microvascular 
lesion formation, but also towards the role of environmental exposures in re-programming 
vascular cells to a more stem cell-like state. In support of this idea, others have already 
shown that the continuous expression of ID3 and Oct-4 de-differentiated mouse embryonic 
fibroblasts into neural stem cells (Moon et al., 2012). Our study lends support for the role of 
ID3 in stemness as demonstrated with EC ID3+ morphologically differentiated into neuronal
— and smooth muscle—like cells. Our results show that EC wt exposed to SU5416 had 
increased expression of transcriptional regulators ID3, Oct-4, and Sox-2. As mentioned 
earlier SU5416 has been reported to expand a population of stem-like cells in the formation 
of microvascular lesions; however, our findings are novel in that we show pluripotent 
transcription factors and stemness markers expressed within only 3h of chemical exposure in 
human vascular cells. SU5416 exposure appears to directly alter biological pathways that 
increase the expression of pluripotent signaling molecules in addition to or alternatively to 
the expansion of an existing population of vascular stem cells.
Our findings indicate that EC ID3+ stem-like cells may serve as a human model of 
microvascular lesions. In this study, we showed similarities in the molecular signature 
shared between an in vitro 3-D human microvascular lesion formed from EC ID3+/PASMC 
cell culture and in vivo microvascular lesions from a rodent model of severe PAH. It is 
probable that several cell types and perhaps several precursor and stem cells contribute to 
the angioobliterative remodeling in PAH. Yet because of the early emphasis on exuberant 
EC growth in idiopathic PAH and the concept that “primitive angioformative cell commit to 
differentiate into endothelial cells” (Tuder et al., 1994b) we have postulated on ECs as one 
cell of origin of microvascular lesions because EC stem-like cells can be involved in 
repairing vascular injury. Using a novel 3-D, we demonstrated that ID3 was essential for EC 
stability and 3-D microvascular lesion formation. The EC ID3+ sustained the growth of 
glomeruloid microvascular lesions in a 3-D cell culture model for up to 90 days, however, it 
is unclear how ID3 overexpression sustained the prolonged growth of this vascular lesion. 
Cell cycle analysis revealed that EC ID3+ resided more in the G0/G1 phase and because a 
higher proliferative capacity may exhaust the stem cell population, our observed increase in 
G0/G1 phase by ID3— thus may help to support our concept of stemness by slowing cell 
cycle progression down. Although we used the EC ID3+ stem-like cells to model pulmonary 
microvascular lesions, the significance of using EC with a stem cell-like molecular signature 
is in its application to study other pathological processes associated with the microvascular 
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lesion formation. Furthermore, this model may allow for studying the early processes 
involved in the development of the vascular lesion.
A large number of environmental factors can potentially influence and de-regulate reactive 
oxygen species (ROS) mediated signaling which may contribute to abnormal vascular 
development or de-differentiation. We hypothesize that switch in the molecular stemness 
profile of ECs may occur during the development of angioproliferative lesions found in 
severe forms of PAH. Based on our EC culture data we expected to see an increase in 
VEGFR3 expression (a marker of endothelial stem-like cells) in microvascular lesions of the 
SuHx model, but not an increase in its expression due to hypoxia alone. VEGFR3 activation 
by ROS has been reported to promote survival of ECs exposed to oxidative stress (Wang et 
al., 2004), and it may be a response to oxidative stress that led to the observed increase in 
VEGFR3 expression of rats exposed to hypoxia alone. Importantly, SU5416-induced 
expression of ID3, VEGFR3, and Pyk2 occurred both in vitro in the human cells and the rat 
microvascular lesions. A detailed exploration of the mechanisms whereby these molecules 
participate in vascular lesion formation will be necessary. Activation of VEGFR3 leads to 
the phosphorylation of Pyk2 which is involved in the coordination of cell growth (Liu et al., 
1997). ID3 and Pyk2 are redox sensitive molecules and an increase in their individual 
expression could be due to oxidative stress that is already known to be generated during the 
3wk chronic hypoxia treatment (Hoshikawa et al., 2001). Several lines of evidence support 
this observation. The non-receptor protein tyrosine kinase Pyk2 is activated by ROS in 
vascular cells while redox signaling has been shown to control ID3 gene expression and 
protein phosphorylation (Frank et al., 2000; Mueller et al., 2002; Felty et al., 2008). Since 
other non-receptor tyrosine kinases have already been shown to regulate Id expression 
(Gautschi et al., 2008), we postulate that ID3 may be a novel target of Pyk2 signaling that is 
triggered by oxidative stress. Thus, reprogramming of ECs to stem-like cells may be 
regulated in part by a redox sensitive VEGFR3→Pyk2→ID3 signaling pathway.
In conclusion, ID3 contributes to the acquisition of a molecular stem cell-like signature—
CD133+ VEGFR3+ CD34+ in human microvascular ECs. Furthermore, under defined cell 
culture conditions EC ID3+ stem-like cells formed a 3-D vascular tissue that morphologically 
resembled glomeruloid microvascular lesions. We demonstrated similarities in the molecular 
stem cell-like signature shared between an in vitro 3-D human microvascular lesion formed 
from EC ID3+/PASMC cell culture and in vivo microvascular lesions from a rodent model of 
severe PAH. Understanding how normal and stem-like cells utilize ID3 may open up new 
avenues for a better understanding of the molecular mechanisms which are underlying the 
pathological development of microvascular lesions in diseases such as proliferative diabetic 
retinopathy, glioblastoma, NSCLC, and IPAH. Potential clinical implications of our data are 
the development of biomarkers and inhibitors of ID3 signaling in the context of treating 
diseases that harbor proliferative microvascular lesions. Because ID3 produces a molecular 
stemness signature in ECs and because EC ID3+ stem-like cells have the capacity to form 3-
D microvascular lesions, our data point towards an important role for ID3 in the 
development of vascular proliferative disorders.
Das et al. Page 15
Microvasc Res. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Acknowledgments
This research is supported by grants from NIH SC3 Award (1SC3GM084827-01A1). We would also like to thank 
Dr. Elena Kaftanovskaya, FIU Department of Human and Molecular Genetics, for her professional expertise and 
kind help with our histology sample preparation.
References
Chow K, Fessel JP, Kaoriihida S, Schmidt EP, Gaskill C, Alvarez D, Graham B, Harrison DG, Wagner 
DH Jr, Nozik-Grayck E, West JD, Klemm DJ, Majka SM. Dysfunctional resident lung 
mesenchymal stem cells contribute to pulmonary microvascular remodeling. Pulm Circ. 2013; 
3:31–49. [PubMed: 23662173] 
Diller GP, Thum T, Wilkins MR, Wharton J. Endothelial progenitor cells in pulmonary arterial 
hypertension. Trends Cardiovasc Med. 2010; 20:22–29. [PubMed: 20685574] 
Fantozzi I, Huang W, Zhang J, Zhang S, Platoshyn O, Remillard CV, Thistlethwaite PA, Yuan JX. 
Divergent effects of BMP-2 on gene expression in pulmonary artery smooth muscle cells from 
normal subjects and patients with idiopathic pulmonary arterial hypertension. Exp Lung Res. 2005; 
31:783–806. [PubMed: 16368652] 
Felty Q, Porther N. Estrogen-induced redox sensitive Id3 signaling controls the growth of vascular 
cells. Atherosclerosis. 2008; 198:12–21. [PubMed: 18281048] 
Frank GD, Motley ED, Inagami T, Eguchi S. PYK2/CAKbeta represents a redox-sensitive tyrosine 
kinase in vascular smooth muscle cells. Biochem Biophys Res Commun. 2000; 270:761–765. 
[PubMed: 10772898] 
Gambaryan N, Perros F, Montani D, Cohen-Kaminsky S, Mazmanian M, Renaud JF, Simonneau G, 
Lombet A, Humbert M. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic 
pulmonary hypertension. Eur Respir J. 2011; 37:1392–1399. [PubMed: 20884740] 
Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara 
DR, Mack PC, Kung HJ. Regulation of Id1 expression by SRC: implications for targeting of the 
bone morphogenetic protein pathway in cancer. Cancer Res. 2008; 68:2250–2258. [PubMed: 
18381431] 
Grau SJ, Trillsch F, Herms J, Thon N, Nelson PJ, Tonn JC, Goldbrunner R. Expression of VEGFR3 in 
glioma endothelium correlates with tumor grade. J Neurooncol. 2007; 82:141–150. [PubMed: 
17115285] 
Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, 
Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel 
NF, Yuan JX, Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J 
Am Coll Cardiol. 2009; 54:S10–S19. [PubMed: 19555853] 
Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelkel NF, Fujimura 
S. Generation of oxidative stress contributes to the development of pulmonary hypertension 
induced by hypoxia. J Appl Physiol (1985). 2001; 90:1299–1306. [PubMed: 11247927] 
Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, Nam DH, Choi YJ, Kim H. EGFR-AKT-Smad 
signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven 
cytokine induction. Cancer Res. 2011; 71:7125–7134. [PubMed: 21975932] 
Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK. 
Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic 
culture. Nat Protoc. 2012; 7:235–246. [PubMed: 22240585] 
Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis 
and induces differentiation. J Cell Biol. 1998; 143:1341–1352. [PubMed: 9832561] 
Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell 
proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998; 
101:927–934. [PubMed: 9486960] 
Li Y, Zhang Q, Yin X, Yang W, Du Y, Hou P, Ge J, Liu C, Zhang W, Zhang X, Wu Y, Li H, Liu K, 
Wu C, Song Z, Zhao Y, Shi Y, Deng H. Generation of iPSCs from mouse fibroblasts with a single 
gene, Oct4, and small molecules. Cell Res. 2011; 21:196–204. [PubMed: 20956998] 
Das et al. Page 16
Microvasc Res. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Liu ZY, Ganju RK, Wang JF, Schweitzer K, Weksler B, Avraham S, Groopman JE. Characterization 
of signal transduction pathways in human bone marrow endothelial cells. Blood. 1997; 90:2253–
2259. [PubMed: 9310476] 
Lowery JW, Frump AL, Anderson L, DiCarlo GE, Jones MT, de Caestecker MP. ID family protein 
expression and regulation in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp 
Physiol. 2010; 299:R1463–R1477. [PubMed: 20881097] 
Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, 
Cherrington JM. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular 
endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000; 6:4848–
4858. [PubMed: 11156244] 
Moon JH, Heo JS, Kwon S, Kim J, Hwang J, Kang PJ, Kim A, Kim HO, Whang KY, Yoon BS, You 
S. Two-step generation of induced pluripotent stem cells from mouse fibroblasts using Id3 and 
Oct4. J Mol Cell Biol. 2012; 4:59–62. [PubMed: 22131360] 
Mueller C, Baudler S, Welzel H, Bohm M, Nickenig G. Identification of a novel redox-sensitive gene, 
Id3, which mediates angiotensin II-induced cell growth. Circulation. 2002; 105:2423–2428. 
[PubMed: 12021231] 
Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al HA, Gomez-Arroyo JG, 
Voelkel NF, Bogaard HJ. New models of pulmonary hypertension based on VEGF receptor 
blockade-induced endothelial cell apoptosis. Pulm Circ. 2012; 2:434–442. [PubMed: 23372927] 
Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, 
McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary 
arterial hypertension in rats. Circ Res. 2007; 100:923–929. [PubMed: 17332430] 
Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer 
paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008; 178:558–
564. [PubMed: 18556624] 
Rojiani AM, Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an 
immunohistochemical and ultrastructural study. J Neurosurg. 1996; 85:1078–1084. [PubMed: 
8929498] 
Sakao S, Taraseviciene-Stewart L, Cool CD, Tada Y, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, 
Tatsumi K, Kuriyama T, Voelkel NF. VEGF-R blockade causes endothelial cell apoptosis, 
expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and 
neuronal-like cells. FASEB J. 2007; 21:3640–3652. [PubMed: 17567571] 
Sakurai D, Tsuchiya N, Yamaguchi A, Okaji Y, Tsuno NH, Kobata T, Takahashi K, Tokunaga K. 
Crucial role of inhibitor of DNA binding/differentiation in the vascular endothelial growth factor-
induced activation and angiogenic processes of human endothelial cells. J Immunol. 2004; 
173:5801–5809. [PubMed: 15494533] 
Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of 
CD34+ lymphatic/vascular endothelial precursor cells. Blood. 2003; 101:168–172. [PubMed: 
12393704] 
Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, El-Bizri N, Sawada H, Haghighat 
R, Chan R, Haghighat L, de JPV, Wang L, Reddy S, Zhao M, Bernstein D, Solow-Cordero DE, 
Beachy PA, Wandless TJ, Ten DP, Rabinovitch M. FK506 activates BMPR2, rescues endothelial 
dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013; 123:3600–3613. [PubMed: 
23867624] 
Tanaka F, Oyanagi H, Takenaka K, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake 
Y, Wada H. Glomeruloid microvascular proliferation is superior to intratumoral microvessel 
density as a prognostic marker in non-small cell lung cancer. Cancer Res. 2003; 63:6791–6794. 
[PubMed: 14583475] 
Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc MG, Waltenberger J, Voelkel NF, Tuder 
RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-
dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 
2001; 15:427–438. [PubMed: 11156958] 
Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of 
inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994a; 
144:275–285. [PubMed: 7508683] 
Das et al. Page 17
Microvasc Res. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of 
inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994b; 
144:275–285. [PubMed: 7508683] 
Tuder RM, Voelkel NF. Plexiform lesion in severe pulmonary hypertension: association with 
glomeruloid lesion. Am J Pathol. 2001; 159:382–383. [PubMed: 11438486] 
Wang JF, Zhang X, Groopman JE. Activation of vascular endothelial growth factor receptor-3 and its 
downstream signaling promote cell survival under oxidative stress. J Biol Chem. 2004; 
279:27088–27097. [PubMed: 15102829] 
Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, 
Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud 
PO. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 
2005; 19:1872–1874. [PubMed: 16141364] 
Yang J, Li X, Li Y, Southwood M, Ye L, Long L, Al-Lamki RS, Morrell NW. Id proteins are critical 
downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. Am J 
Physiol Lung Cell Mol Physiol. 2013; 305:L312–L321. [PubMed: 23771884] 
Das et al. Page 18
Microvasc Res. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Highlights
• ID3 overexpression significantly increased stemness markers in endothelial cells
• ID3 overexpression resulted in vascular stem cell signature—CD133+ 
VEGFR3+ CD34+
• ID3 overexpressing cell phenotype was similar to microvascular glomeruloid 
lesions
• VEGFR inhibitor SU5416 significantly altered stemness markers in endothelial 
cells
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Fig. 1. Molecular endothelial stem signature induced by ID3 overexpression
Cell surface expression of endothelial stem markers CD133, VEGFR3, CD34 was analyzed 
by two color flow cytometry. (A) Representative flow cytometry data analysis of EC wt and 
EC ID3+ analyzed for the co-expression of endothelial marker CD34 and stem marker 
CD133. (B) Representative flow cytometric analysis of CD34 and VEGFR3 co-expression 
in EC wt and EC ID3+. (C) CD133+ cells were approximately 7-fold higher in EC ID3+ 
compared to EC wt. Bar graph represents the flow cytometric data for CD133 and CD34 co-
expression from three independent experiments ± SD. (D) VEGFR3+ cells were 
approximately 5-fold higher in EC ID3+ compared to EC wt. (E) Representative flow 
cytometry data analysis of EC wt and EC ID3+ analyzed for the co-expression of Sox2 and 
Oct4. (F) Representative flow cytometric analysis of CD31 and Pyk2 co-expression in EC wt 
and EC ID3+. (G) Sox2 and Oct4 positive cells were approximately 6.7-fold higher in 
EC ID3+ compared to EC wt. Bar graph represents the flow cytometric data for Sox2 and 
Oct4 co-expression from three independent experiments ± SD. (H) Pyk2 and CD31 positive 
cells were approximately 7-fold higher in EC ID3+ compared to EC wt. Graph of flow 
cytometric data for Pyk2 and CD31 co-expression derived from three independent 
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experiments ± SD. Each column represents mean marker expression in either EC ID3+ 
**p<0.01 vs. EC wt for increase; or EC ID3+ b p<0.01 vs. EC wt for decrease. Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons.
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Fig. 2. Continuous ID3 expression increased the population of cells in the G0/G1 phas
The cell cycle distribution of EC ID3+ compared to EC wt was determined by flow 
cytometry. (A) Representative flow cytometry histogram of percent DNA content distributed 
among the cell cycle phases based on PI fluorescence for EC wt (left panel) and EC ID3+ 
(right panel). (B) EC ID3+ showed a statistically significant 1.2-fold increase in cells residing 
in the G0/G1 phase compared to EC wt. This graph represents the mean of three independent 
experiments for cell cycle distribution of EC wt and EC ID3+ ± SD. Each column represents 
% DNA content in cell cycle phases of either EC ID3+ **p<0.01 vs. EC wt for increase 
and bp<0.01 vs. EC wt for decrease. Data were analyzed by ANOVA; Tukey HSD test for 
multiple comparisons.
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Fig. 3. SU5416-induced ID3, VEGFR3, and Pyk2 expression in microvascular ECs
EC wt was exposed to SU5416 [3μM] for 3h. Co-localization of target molecules was 
performed by immunofluorescence confocal microscopy. Cells were immunostained with 
antibodies against ID3 (blue), VEGFR3 (red), Pyk2 (green). (A) Immunofluorescent 
detection of ID3, VEGFR3, or Pyk2 in vehicle control (left panel) and SU5416 treated cells 
(right panel). Representative photomicrographs obtained by confocal microscopy are from 
one of three separate experiments. Scale bar = 70 μm (B) Percent of cells expressing each 
marker when treated with SU5416. EC wt exposed to SU5416 were 44% ID3+, 65% 
VEGFR3+, and 70% Pyk2+ compared to less than 5% in the vehicle control. The error bars 
represent the mean of expressed marker positive cells ± SD in 15 observed chambers of the 
slides. ** p<0.01 vs. control. Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons. (C) Western blots for ID3, VEGFR3, Sox2, Oct4, and CD34 were used to 
determine SU5416-induced protein expression in treated EC wt and EC ID3+.
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Fig. 4. 
Pluripotent transcription factors Oct-4 and Sox-2 are induced by SU5416 in microvascular 
ECs. Since in vivo SU5416 exposure was recently reported to produce Oct-4+ cells within 
lung vascular lesions, we determined whether Oct-4 and Sox-2 expression increased in 
EC wt when exposed to SU5416. Cells were treated with SU5416 [5μM] for 3h and then 
cultured in fresh media for four days. Cells were immunostained with antibodies against 
CD31 (blue), Oct-4 (red), Sox-2 (green). Co-localization of relevant molecules was 
performed by confocal microscopy after immunofluorescence staining. (A) 
Immunofluorescent detection of Oct-4, Sox-2, or CD31 in vehicle control (top row) and 
SU5416 treated cells (bottom row). Representative images are from one of three 
experiments. Scale bar = 70 μm (B) Percent of cells expressing each marker when exposed 
to SU5416. For each group, 100 immunofluorescent cells were counted. In control, the cells 
that were scored 1 IF were counted and expressed as a percentage. In SU5416 group, cells 
that were scored 2 IF and 3 IF were counted and expressed as a percentage as described in 
Materials and Methods section. EC wt exposed to SU5416 were approximately 90% positive 
for Oct-4 and Sox-2 compared to less than 10% in the vehicle control. There was 90% co-
localization of endothelial marker CD31 with these transcription factors. The error bars 
represent the mean of expressed marker positive cells ± SD.
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Fig. 5. SU5416 treated microvascular ECs form spheroids expressing Oct-4 and Sox-2
The novel conditions of treating EC wt with SU5416 in the sphere forming assay was used to 
verify chemical-induced pluripotent transcription factors observed previously in monolayer 
culture. EC wt were seeded at clonal density and cultured as spheroids in DMEM-F12 B27® 
serum-free media with or without SU5416 treatment. Cells were immunostained with 
antibodies against Oct-4 (red) and Sox-2 (green). Co-localization of relevant molecules was 
performed by confocal microscopy after immunofluorescence staining. (A) 
Immunofluorescent staining of Oct-4 and Sox-2 in EC wt. Vehicle control is shown in top 
row with SU5416 treated cells below. Representative images are from one of three 
experiments. Scale bar = 70 μm (B) Graph of EC wt spheroid diameter vs. time. SU5416 
treatment showed a significant increase in spheroid diameter at days 2 and 4 when compared 
to vehicle control. The error bars represent the mean of expressed marker positive cells ± 
SD.
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Fig. 6. EC ID3+ stem-like cells display pluripotent morphology
(A) EC ID3+ stem-like cells were differentiated under defined SMC or neuronal media. 
Images are from phase-contrast microscopy. EC ID3+ were cultured as spheroids for 7d 
followed by 7d monolayer culture with differentiation medium. For SMC-like morphology 
spheroids were cultured with DMEM-F12 containing SMGS (Gibco). For neuron-like cells 
spheroids were cultured with Neurobasal® Medium (Gibco), StemPro® Neural Supplement 
(Gibco) and NGF-7s (Sigma). Magnification X 200. (B) Cell differentiation markers were 
determined using immunofluorescence at days 7, 14, and 28. For immunofluorescence 
imaging studies, slides were incubated with primary antibodies anti-CD34, α-smooth muscle 
actin (α-SMA), and β-tubulin III. Nuclei were counterstained with DRAQ5®. Scale 
bar=20μm. Images were captured with DeltaVision ELITE Olympus IX71 fluorescence 
microscope, Applied precision (Thermo Scientific) using software softWoRx-Acquire 
Version: 5.5.1 Release 3.
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Fig. 7. EC ID3+ form 3-D microvascular lesions
In vitro microvascular lesion formation by EC ID3+ was determined in 3-D culture when 
grown with PASMCs. Both the EC wt and EC ID3+ were seeded with PASMCs to form 
EC/SMC spheroids that were then transferred into well inserts containing a pre-cast 3-D gel 
matrix. Next, well inserts were cultured at 37°C for 90 days with a fresh change of serum-
free DMEM-F12 supplemented with B27® every 15 days. (A) Diagrammatic representation 
of 3-D cell culture protocol. (B) Representative photomicrograph showing 
neovascularization and capillary-like formation among the spheroids in 3-D matrix. The 
spheroid indicated by the red arrow and capillary-like structure shown by the blue arrow. 
Scale bar=100 μm. (C) In graph, red line shows increasing number of tube structures from 
EC ID3+/SMC spheroids per well during the 90 day time period. (D) Representative 
photomicrograph of the H&E stained tube-like structure. Green arrow indicates the small 
circular morphology of ECs while the black arrow indicates the bigger spindle shaped 
PASMCs. Scale bar=50 μm. (E) Representative photomicrograph of the H&E stained 
spheroid cross-section with intact cellular core and lumen-like structures. (F) Co-localization 
of EC with SMC was determined by confocal microscopy after immunofluorescent staining 
of cells with antibodies against endothelial marker CD34 (green), smooth muscle marker α-
SMA (blue), and ID3 (red). Representative images (top panel) show SMCs organize along 
the capillary-like structures and ECs composed the spheroid core. Bottom panel shows co-
localization of ID3 overexpression with EC marker CD34. (G) Graph depicts percent of 
cells expressing each marker. Approximately 45% of the cells immunostained positive for 
α-SMA, 90% stained positive for endothelial marker CD34, and 80% stained positive for 
ID3. The error bars represent the mean of expressed marker positive cells ± SD in slides.
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Fig. 8. In vivo pulmonary vascular lesions overexpress ID3, VEGFR3, and Pyk2
In vivo pulmonary vascular lesions overexpress ID3, VEGFR3, and Pyk2. Lung vascular 
lesions from the rodent SuHx model of severe PAH were stained with antibodies against: 
ID3 (blue), VEGFR3 (red), and Pyk2 (green) followed by immunofluorescent detection by 
confocal microscopy. (A) Both vehicle control and 3 wk chronic hypoxia treatment groups 
showed a uniform monolayer of cells lining the lumen of the pulmonary artery. SU5416-
treated lungs exposed to chronic hypoxia for 3 wk (bottom row) showed a partially blocked 
lumen with cells stacked on top of each other instead of forming a monolayer. 
Representative images are from one of three lungs per group. Scale bar = 70 μm (B) Percent 
of cells expressing each marker amongst treatment groups when treated with vehicle control, 
hypoxia only, and SU5416 + hypoxia. Error bars represent the mean of expressed marker 
positive cells ± SD. ** p<0.01 vs. Control in normal/control (810), exposed in hypoxia and 
Sugen 5416/chronic hypoxia condition of lung tissue. Data were analyzed by ANOVA; 
Tukey HSD test for multiple comparisons.
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